Healthy Gut

The Healthy Human Gut Microbiome and Human Health: An Evidence-Based Assessment

• There is no single "healthy" gut microbiome and no consensus reference standard — the field has converged instead on the idea that health depends on the functions a microbial community performs (fiber fermentation into short-chain fatty acids, immune training, barrier maintenance, colonization resistance), which many different microbial compositions can deliver through "functional redundancy." Higher diversity is broadly associated with health but is necessary-not-sufficient and not always desirable.
• The strongest, best-established science is: fiber/plant-diverse and fermented-food diets favorably shape the microbiome and lower inflammation; SCFAs (especially butyrate) are genuinely important to gut and immune biology; fecal microbiota transplantation (FMT) is proven for recurrent C. difficile (two FDA-approved products since 2022–2023); and antibiotics, diet, birth mode, and several common drugs measurably reshape the community. Much disease evidence (obesity, depression, Parkinson's, Alzheimer's) is correlational in humans and causal mainly in mice — a crucial distinction.
• The hype substantially outruns the science in three areas: direct-to-consumer microbiome testing kits (not clinically validated, inconsistent between companies, no FDA-approved diagnostic), most over-the-counter probiotics (strain-, dose-, and person-specific effects; weak general-population evidence), and causal claims about the "gut-brain axis." Spend on fiber and food diversity; be skeptical of tests and supplements.

Key Findings

1. "Healthy" is defined functionally, not compositionally. The 2024 Gut review by Van Hul, Cani, Petitfils, De Vos, Tilg and El-Omar ("What defines a healthy gut microbiome?") and the Human Microbiome Project both concluded there is no universal taxonomic signature of health. Different people carry very different microbes that perform overlapping jobs.
2. Diversity is a useful but imperfect marker. Lower diversity tracks with IBD, C. difficile, obesity and many chronic diseases; higher diversity appears in non-industrialized populations. But diversity can be high in constipation and is "necessary but not sufficient" — it does not by itself cause health.
3. Key beneficial taxa exist but are not magic bullets. Butyrate-producers like Faecalibacterium prausnitzii and Roseburia, mucin-specialist Akkermansia muciniphila, and Bifidobacterium are consistently depleted in disease, but their loss is often a marker as much as a cause.
4. Enterotypes are now seen as a simplification. The original 2011 three-enterotype model (Bacteroides/Prevotella/Ruminococcus) is increasingly viewed as a continuous gradient rather than discrete categories; the concept is still debated and used cautiously.
5. Core functions are well-characterized: SCFA production, vitamin synthesis (K, B12, folate, biotin), bile-acid metabolism, immune training, mucus/barrier maintenance, colonization resistance, and gut-brain signaling.
6. Diet is the most powerful modifiable lever. Fiber diversity, fermented foods, and Mediterranean-style eating are the best-supported interventions.
7. FMT for recurrent C. difficile is the field's clearest clinical win. Everything else (FMT for other conditions, most probiotics, testing kits) ranges from promising-but-experimental to oversold.

Details

1. What defines a "healthy" gut microbiome?

There is no consensus single definition and no validated "reference" healthy microbiome. As science journalist Kristina Campbell summarizes the consensus, after hundreds of studies and several large initiatives "we still don't have a clear idea what characterizes a healthy gut microbiota." The most robust generalization is that healthy people tend to show greater microbial diversity than people with chronic disease — but this is an association, not an established cause.

Diversity and richness. Researchers distinguish richness (how many species) from evenness (how balanced their abundances), summarized in alpha-diversity metrics like the Shannon index. Lower Shannon diversity is reported in IBD and enteric infections; higher diversity in hunter-gatherer communities. Important caveats: (a) diversity is necessary but not sufficient — you cannot easily be healthy without it, but having it does not guarantee health; (b) higher diversity is sometimes worse, e.g., it accompanies slow colonic transit/constipation; and (c) work toward "an improved definition of a healthy microbiome for healthy aging" (analyzing ~21,000 gut microbiomes) found that "uniqueness," sometimes cast as a marker of healthy aging, is not a uniformly desirable feature and that terms like diversity "need greater precision."

Functional redundancy and the "core" microbiome. The dominant modern framing is that many different compositions can deliver the same functions — "functional redundancy." The human gut is dominated by a handful of phyla (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Verrucomicrobia) and contains an estimated 150–400 species per person, but the functional gene repertoire (e.g., carbohydrate-degrading enzymes, SCFA pathways) is more conserved across people than the species list. A "core microbiome" — taxa shared by most healthy people — exists more clearly at the functional/genus level than at the species/strain level.

Key beneficial taxa. Faecalibacterium prausnitzii is one of the most abundant gut bacteria in health: per Martín, Bermúdez-Humarán and Langella (Frontiers in Microbiology 2018), it "represents approximately 5% of the total fecal microbiota in healthy adults being one of the most abundant bacterium in the human intestinal microbiota of healthy adults" (and can reach ~15% in some individuals). It is a major butyrate producer and anti-inflammatory commensal, identified as such in Crohn's patients by Sokol et al. (PNAS 2008), and is depleted in IBD, IBS, colorectal cancer, obesity, celiac disease and in frail elderly. Akkermansia muciniphila (1–3% of microbiota) lives in the mucus layer and supports barrier function; it is reduced in IBD, obesity, type 2 diabetes and autism associations. Bifidobacterium dominates the breastfed-infant gut; Roseburia is another key butyrate producer; Lactobacillus species are common probiotics. Crucially, these are biomarkers as much as drivers — their depletion frequently reflects disease and diet rather than causing it, and strain-level differences matter (e.g., F. prausnitzii has multiple clades with different functions).

Enterotypes. Proposed by Arumugam et al. (Nature 2011) as three clusters dominated by Bacteroides, Prevotella or Ruminococcus. The concept was influential but is now heavily qualified: a 2014 Cell Host & Microbe re-analysis ("Rethinking 'Enterotypes'") argued that "evidence against discrete community types… is accumulating rapidly" and that variation is largely continuous; an individual's enterotype "can be highly variable." A 2018 reconciling review (Costea et al., Nature Microbiology) recommended treating enterotypes as a useful descriptive tool rather than discrete biological categories. The Estonian biobank cohort (n=2,506) found enterotypes have limited clinical-diagnostic value and are less stable than once thought. Bottom line: enterotypes are a convenient shorthand, not fixed "blood-type"-like states.

2. Major functions of a healthy gut microbiome

• Short-chain fatty acids (SCFAs). Bacterial fermentation of dietary fiber produces acetate, propionate and butyrate. Per the 2024 Nature Reviews Immunology review, these regulate epithelial barrier function and mucosal/systemic immunity via G-protein-coupled receptors and histone-deacetylase (HDAC) inhibition. Butyrate is the primary energy source for colonocytes, strengthens tight junctions, and drives differentiation of regulatory T cells and other immune cells — among the most mechanistically solid microbiome biology we have.
• Vitamin synthesis. Gut bacteria synthesize vitamin K and several B vitamins (B12, folate, biotin), contributing to host supply.
• Bile-acid metabolism. Bacteria convert primary to secondary bile acids; this is part of how Vowst (see below) is thought to resist C. difficile — restoring the primary/secondary bile-acid balance.
• Immune training and regulation. A large fraction of the immune system is associated with the gut; microbes are essential for normal development of gut-associated lymphoid tissue, IgA-secreting plasma cells, and T-cell balance (germ-free mice have atrophic Peyer's patches and immune deficits).
• Barrier/mucus maintenance. Mucin-feeders like Akkermansia and butyrate support the mucus layer and epithelial integrity.
• Colonization resistance. A healthy community resists pathogen invasion — the principle underlying FMT's success against C. difficile.
• Gut-brain axis. Bidirectional signaling via the vagus nerve, immune mediators, the HPA axis, and microbial metabolites. Gut bacteria produce or stimulate neurotransmitters (GABA, dopamine precursors, and influence serotonin). Per Gershon and Tack (2007), enterochromaffin (EC) cells "produce ~95% of total body serotonin (5-HT), including all plasma 5-HT," with roughly 90% stored in the gut and only ~5% in the CNS; SCFAs upregulate tryptophan hydroxylase 1 (TPH1), the rate-limiting enzyme for serotonin synthesis. However, gut-derived serotonin does not cross the blood-brain barrier, so the mechanistic link to mood is more indirect and less proven than popular accounts suggest.

3. What shapes the gut microbiome

• Diet (the dominant lever). Fiber/"microbiota-accessible carbohydrates," plant diversity, fermented foods, and the Mediterranean diet are the best-supported positive influences; the Western diet (low fiber, high fat/sugar, additives) is associated with reduced diversity and inflammation. The landmark Stanford randomized trial (Wastyk, Fragiadakis et al., Cell 2021; Sonnenburg and Gardner labs, n=36 completers) found a fermented-food diet increased microbiome diversity and decreased 19 inflammatory proteins, while a high-fiber diet did not raise diversity over the short term — suggesting industrialized guts may be depleted of fiber-degrading microbes and that fiber may need a longer period or to be accompanied by deliberate microbial introduction.
• Artificial sweeteners and emulsifiers. Suez et al. (Nature 2014, Weizmann) showed non-caloric artificial sweeteners "induce glucose intolerance by altering the gut microbiota" in mice and a subset of humans, with effects transferable to germ-free mice by FMT. A later human RCT (Suez et al., Cell 2022) confirmed sweeteners alter human microbiomes and glycemic responses in a person-specific way. Dietary emulsifiers have been linked to gut inflammation in mouse and some human studies. These are real signals but still maturing.
• Mode of birth. Vaginally delivered infants acquire maternal gut/vaginal microbes (more Bifidobacterium, Bacteroides); C-section infants are colonized more by skin/oral/hospital microbes (more Enterococcus, Klebsiella, Enterobacter) and show delayed Bacteroides and Bifidobacterium. Associations exist with later asthma, allergy, obesity, but causality is unsettled.
• Breastfeeding. Human milk oligosaccharides (HMOs) feed infant-type bifidobacteria, shaping immune maturation in the "first 1,000 days." Breastfeeding partly restores Bifidobacterium after C-section.
• Antibiotics and other drugs. One antibiotic course can sharply reduce diversity. A landmark Dutch metagenomic study (Vich Vila et al., Nature Communications 2020) found ~46% of 41 common drug categories associate with microbiome features; proton-pump inhibitors (PPIs), metformin, laxatives, and antibiotics had the strongest effects. PPIs increase oral-type bacteria in the gut; metformin increases SCFA-producers (part of its therapeutic effect, and possibly its GI side effects). Effects can persist years after use.
• Age. The microbiome assembles over the first ~3 years, is relatively stable in adulthood, and becomes more variable and often less diverse in older age. The ELDERMET cohort (Claesson et al., Nature 2012, n=178) showed gut composition correlates with diet and health, and that loss of community-associated diversity correlates with frailty and inflammation, with long-stay-care residents less diverse than community dwellers.
• Exercise, sleep, stress. Each is associated with microbiome differences (e.g., exercise with more SCFA-producers; stress/HPA-axis activation with composition shifts), but human causal evidence is comparatively thin.
• Geography/industrialization — the "disappearing microbiome." Justin and Erica Sonnenburg (Stanford) and Martin Blaser (Rutgers/NYU, Missing Microbes) argue industrialization — antibiotics, C-sections, low-fiber diets, sanitation — has progressively depleted microbial diversity across generations ("The vulnerability of the industrialized microbiota," Science 2019), coinciding with rising chronic inflammatory disease. Non-industrialized populations (e.g., Hadza) carry markedly more diverse microbiomes with taxa largely absent in industrialized guts. This is a compelling and influential hypothesis but remains partly inferential.

4. Evidence linking the microbiome to specific conditions

A consistent theme: strong associations in humans, causal proof mostly in mice. Germ-free-mouse FMT experiments repeatedly transfer phenotypes (obesity, metabolic and behavioral traits) from human donors to mice, but human causal confirmation is far rarer.

• IBD (Crohn's, ulcerative colitis): Among the strongest associations — reduced diversity, depleted F. prausnitzii, altered SCFAs. Dysbiosis is integral to disease, though whether it is primary cause or consequence of inflammation remains debated. SCFA/butyrate therapy shows mechanistic promise but inconsistent clinical-trial results.
• IBS: Associated with altered composition and is the target of diet (low-FODMAP), probiotics, and (experimentally) FMT, with mixed results.
• Obesity and metabolic syndrome: Classic germ-free studies (Turnbaugh, Gordon lab) showed obesity phenotypes transfer to mice via microbiota, including from discordant human twins. But human FMT trials for weight (e.g., FMT-TRIM, PLOS Medicine 2020) have been disappointing, suggesting the microbiome's role in human body weight is smaller than mouse data imply.
• Type 2 diabetes: Associated with altered composition and reduced butyrate-producers; metformin confounds many studies because it itself reshapes the microbiome.
• Cardiovascular disease (TMAO): Stanley Hazen's Cleveland Clinic group showed gut bacteria convert dietary choline/L-carnitine (red meat, eggs) to TMA, which the liver oxidizes to TMAO, mechanistically linked to atherosclerosis in mice and associated with cardiovascular events and heart failure in humans. Caveat: the human association is substantially mediated by kidney function, one Mendelian-randomization study found no causal link, and reviews conclude there is "no fully conclusive evidence that TMAO is a causal factor" in humans — among the better mechanistic stories, but not settled.
• Colorectal cancer (CRC): Fusobacterium nucleatum is enriched in CRC tumors and associated with recurrence, metastasis and poorer prognosis. Mechanisms include the FadA adhesin activating E-cadherin/β-catenin (Wnt) signaling to drive proliferation (Rubinstein et al., Cell Host & Microbe 2013, which explicitly noted "causality and underlying mechanisms remain to be established") and the Fap2 adhesin binding tumor-overexpressed Gal-GalNAc and the immune-checkpoint receptor TIGIT to evade immunity (Abed et al., Cell Host & Microbe 2016; structurally confirmed in Nature Communications 2025). A 2024 Nature study from the Bullman and Johnston labs at Fred Hutchinson Cancer Center (Zepeda-Rivera et al., Nature 628:424–432) generated closed genomes for 135 strains and identified a specific subspecies clade — F. nucleatum animalis "Fna C2" — that "dominates the colorectal cancer niche," is enriched in tumor versus adjacent normal tissue (116-patient and 627-stool cohorts), and uniquely promotes intestinal adenomas and pro-oncogenic metabolites in mice (whereas the sister clade Fna C1 did not differ from controls). Press coverage links this subtype to growth in "up to 50% of human colorectal cancers." Causation in humans remains associative; the strong causal evidence is mechanistic/preclinical (cell and mouse models), and the literature still openly debates Fn as "causal factor or passenger."
• Allergies and asthma: Early-life microbiome disruption (C-section, antibiotics, low diversity) is associated with later allergic disease (the "hygiene"/"old friends" framing); reduced F. prausnitzii/Akkermansia reported in allergic children. Associative.
• Autoimmune conditions: Associations exist (e.g., multiple sclerosis, lupus, rheumatoid arthritis) with mechanistic mouse support; human causal evidence limited.
• Mental health (depression, anxiety): Observational studies consistently find compositional differences (e.g., depleted butyrate-producers, altered Oscillibacter/Alistipes). Animal studies show specific strains alter stress behavior via the vagus nerve. But, as John Cryan (a leading microbiome-gut-brain researcher) cautions, "most data come from observational studies where cause and effect remain unclear," and meta-analyses of "psychobiotics" for anxiety show minimal/no effect. Promising but not proven in humans.
• Neurodegeneration (Parkinson's, Alzheimer's): Parkinson's has notable evidence: α-synuclein pathology may begin in the gut and spread via the vagus nerve; appendectomy is associated with lower PD risk; PD patients show altered microbiota and reduced SCFA-producers; gut bacteria are causal to symptoms in mouse models. Alzheimer's associations are earlier-stage. Again, human causation unproven.

5. Interventions and the actual strength of evidence

Strong / well-established:

• Dietary fiber and plant diversity — the best-supported approach to feeding SCFA-producers. The "~30 plants per week" heuristic comes from McDonald et al. (mSystems 2018, the American Gut Project), which found participants eating >30 different plant types per week had significantly more diverse gut microbiomes (and more SCFA-producing taxa) than those eating ≤10, with plant diversity predicting microbiome diversity better than self-reported labels like "vegan" or "omnivore."
• Fermented foods — the Stanford Cell 2021 RCT provides unusually clean human evidence of increased diversity and reduced inflammation.
• FMT for recurrent C. difficile — the clearest clinical success. Per Baunwall et al. (eClinicalMedicine 2020), repeat FMT achieves "an overall 91% effect rate at week 8 and a number needed to treat of 1.5 compared with standard antibiotics," with donor FMT outperforming autologous FMT (90.9% vs 62.5%). The FDA has since approved two standardized products: Rebyota (fecal microbiota, live-jslm; enema; Nov 2022) and Vowst (fecal microbiota spores, live-brpk; oral; April 2023). In the PUNCH CD3 program (267 patients), Rebyota's estimated treatment success was 70.6% vs 57.5% for placebo; in the phase 3 ECOSPOR III trial (SER-109/Vowst, 182 patients), recurrence at 8 weeks was 12% vs 40% for placebo (P<.001), i.e., 87.6% recurrence-free vs 60.2%, with open-label ECOSPOR IV showing 91.3% recurrence-free at week 8 sustained in 94.6% through week 24.

Moderate / mixed / context-dependent:

• Prebiotics (inulin, FOS, GOS) — can increase specific taxa (e.g., bifidobacteria) but in frail elderly did not change global diversity.
• Probiotics — genuine evidence for specific strains in specific indications (e.g., antibiotic-associated diarrhea, some C. difficile prevention, certain infant conditions), but general-population "boost your gut" claims are weak. The Weizmann group (Zmora, Suez, Segal, Elinav; Cell 2018) showed probiotics meet person-specific mucosal "colonization resistance" — they often pass through without colonizing, and stool presence doesn't reflect gut-mucosa colonization. A companion study found probiotics actually delayed microbiome recovery after antibiotics versus spontaneous recovery or autologous FMT. Effects are strain-, dose-, and host-specific.
• Synbiotics (pre+probiotic combinations) — plausible, limited robust human outcome data.
• Time-restricted eating / polyphenols — polyphenols (in coffee, berries, etc.) consistently associate with favorable taxa in observational data (ZOE/PREDICT); time-restricted eating shows metabolic signals but microbiome-specific causal evidence is preliminary.

FMT beyond C. difficile — experimental for IBD (some signal in ulcerative colitis), obesity/metabolic disease (mostly negative in humans so far), autism, and others. Not approved or recommended outside trials.

6. Recent developments (2023–2026)

• Multi-omics and metabolomics are now central — moving from "who is there" (16S/metagenomics) to "what are they doing" (metabolites, transcriptomics). Blood-metabolome signatures can predict gut diversity.
• Personalized nutrition. The foundational work is Zeevi et al. (Cell 2015, Segal & Elinav, Weizmann): the authors "continuously monitored week-long glucose levels in an 800-person cohort, measured responses to 46,898 meals, and found high variability in the response to identical meals, suggesting that universal dietary recommendations may have limited utility." They built a machine-learning algorithm integrating microbiome and clinical data to predict personalized glucose responses, validated it in an independent cohort, and ran "a blinded randomized controlled dietary intervention based on this algorithm [that] resulted in significantly lower postprandial responses and consistent alterations to gut microbiota configuration." This launched the personalized-nutrition field and underpins ZOE.
• ZOE / PREDICT (Spector, Segata, Berry). PREDICT 1 (Nature Medicine 2021) identified panels of ~15 "good" and ~15 "bad" gut microbes linked to cardiometabolic markers (e.g., Prevotella copri and certain butyrate-producers with better glucose control). A 2025 Nature paper (Spector et al.) expanded this to over 34,000 participants and a "ZOE Microbiome Health Ranking 2025" of favorable/unfavorable species, reproducible across 7,800+ additional samples. ZOE's METHOD RCT (Nature Medicine 2024) reported that personalized recommendations improved weight, waist circumference, HbA1c and triglycerides versus standard guidelines. Note the commercial interest: ZOE is both a research enterprise and a paid product (test kit roughly $300–500; membership ~$25/month).
• Live biotherapeutic products (LBPs) — Rebyota and Vowst are the first of a new regulated drug class; defined-consortium products (e.g., VE303) are in trials, pointing toward standardized, donor-independent "microbiome drugs."
• Direction of travel: strain-level resolution, causal/mechanistic studies, engineered consortia and next-generation probiotics (e.g., Akkermansia, F. prausnitzii), and integration with the immune system and metabolism.

7. Hype versus substance

Well-established:

• The microbiome performs essential metabolic/immune functions; SCFAs and barrier biology are real.
• Diet (fiber, fermented foods, diversity) measurably and beneficially shapes it.
• Antibiotics and several common drugs disrupt it.
• FMT cures most recurrent C. difficile.

Genuinely uncertain or contested:

• Whether dysbiosis causes most chronic diseases or is a consequence/marker.
• The magnitude of the gut's influence on the human brain and body weight (mouse data overstate it).
• TMAO causality (confounded by kidney function).
• Whether any "diversity score" is clinically actionable.

Oversold / weak:

• Direct-to-consumer microbiome testing kits ($100–500). A 2024 Science Perspective (Ravel and colleagues) called for regulation; investigators found wildly inconsistent results when the same sample is sent to different companies (documented by Scientific American's seven-test comparison), and gastroenterologists note these tests are "not clinically validated" and rarely change clinical management. No FDA-approved microbiome diagnostic exists. A 2025 international consensus of 69 experts from 18 countries discouraged direct-to-consumer self-testing, advised against reporting the Firmicutes/Bacteroidetes ratio (insufficient evidence) and unvalidated "dysbiosis indices."
• Most OTC probiotic supplements for general "gut health" in healthy people — weak evidence; benefits, where real, are strain- and indication-specific.
• Many "microbiome-optimizing" supplements, cleanses, and personalized-diet products marketed ahead of the evidence.

Elinav and colleagues' own book chapter is aptly titled "Our Microbiome: On the Challenges, Promises, and Hype," concluding that "live microbial therapy is currently limited in efficacy."

Recommendations

For an individual wanting to support gut health (do these now — strong evidence, low cost, low risk):

1. Eat more and more-diverse plant fiber — vegetables, legumes, whole grains, nuts, seeds, fruit. Variety matters as much as quantity; the American Gut Project's ">30 different plants per week" target is a reasonable, evidence-anchored heuristic.
2. Add fermented foods (yogurt with live cultures, kefir, sauerkraut, kimchi, kombucha) — the best human RCT evidence for raising diversity and lowering inflammation.
3. Favor a Mediterranean-style pattern; minimize ultra-processed foods, added sugar, and likely artificial sweeteners and emulsifiers (precautionary).
4. Use antibiotics only when genuinely needed, and avoid unnecessary long-term PPIs — discuss deprescribing with a clinician.
5. Exercise, sleep well, and manage stress — plausibly beneficial for the microbiome, and certainly beneficial for overall health.

Spend cautiously: 6. Skip direct-to-consumer microbiome testing kits for now — not validated, results inconsistent, rarely actionable. Revisit only if/when an FDA-authorized clinical diagnostic emerges. 7. Don't rely on probiotic supplements for general wellness. Use a specific, clinically studied strain only for a specific indication (e.g., preventing antibiotic-associated diarrhea), ideally with clinician input. Don't expect supplements to permanently "colonize" your gut. 8. Reserve FMT for recurrent C. difficile under medical care (now via approved products). Do not attempt DIY FMT or seek it for weight loss, mood, or autism outside a clinical trial.

Thresholds that would change this advice: an FDA-authorized microbiome diagnostic with demonstrated clinical utility; positive, replicated, adequately powered human RCTs of specific probiotic strains or FMT for a given condition; or Mendelian-randomization/intervention evidence establishing causality (rather than association) for a disease. Until then, invest in food, not tests and pills.

Caveats

• Correlation vs causation is the field's central limitation. Most human microbiome-disease links are associations; the dramatic causal results largely come from germ-free-mouse transplants, which do not replicate human physiology. Treat "mice" and "humans" as different evidence tiers.
• Reverse causation and confounding are pervasive — diet, disease, transit time, and especially medications (metformin, PPIs, antibiotics, laxatives) all reshape the microbiome and confound disease comparisons.
• Methodology is not standardized — sampling, storage, sequencing (16S vs shotgun), and bioinformatics choices materially change results, undermining cross-study and cross-company comparability.
• Stool ≠ gut. Fecal samples imperfectly represent the mucosa and different gut regions.
• "Diversity = health" is an oversimplification — necessary-not-sufficient, sometimes undesirable, and not a validated clinical target.
• Commercial conflicts of interest pervade the consumer-facing parts of this field (testing companies, supplement makers, and even research-linked products like ZOE); weigh claims accordingly.
• The science is moving fast. Specific taxa, rankings, and products cited here (e.g., ZOE's 2025 ranking, new LBPs) reflect 2023–2026 understanding and will continue to evolve.